What Analysts Are Saying About DermTech Stock
Portfolio Pulse from Benzinga Insights
DermTech (NASDAQ:DMTK) received mixed analyst ratings with a shift towards a more cautious stance in the last quarter. The average 12-month price target was adjusted to $1.41 from a previous $3.25, indicating a significant downward revision. Analysts from Lake Street, Stephens & Co., and BTIG provided updates, with actions ranging from maintaining to lowering ratings and price targets. DermTech's financial overview shows a positive revenue growth rate of 31.06% but challenges in debt management and net margin.
April 19, 2024 | 5:01 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
DermTech's analyst ratings have become more cautious, with a significant reduction in the average price target to $1.41 from $3.25. The company shows positive revenue growth but faces challenges in debt management and profitability.
The downward revision in DermTech's price target by analysts reflects growing concerns about the company's financial health and market position. Despite positive revenue growth, the high net margin loss and debt management issues are likely to negatively impact investor sentiment and stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100